Amoeba Competitors and Similar CompaniesClear all
Amoeba's competitors and similar companies include Eyenovia and CellFE.
 Amoeba Amoeba SA is a France-based company that develops, manufactures and markets biological products. |  Eyenovia Eyenovia is a late-stage biopharmaceutical company with three lead programs in glaucoma, mydriasis and dry eye with a transformative ophthalmic delivery platform. |  CellFE CellFE is a company that develops a microfluidic device designed to deliver gene-editing molecules into the human cells. | |
Founding Date | Founding Date 2010 | Founding Date 2014 | Founding Date 2018 |
Type | Type Public | Type Public | Type Private |
Tags | |||
Locations | Locations Chassieu, FR HQ Montréal, CA | Locations New York, US HQ | Locations Alameda, US HQ |
Employees | Employees 1436% decrease | Employees 22100% increase | Employees 287% decrease |
Valuation ($) | Valuation ($) 35.2 m | Valuation ($) 47.3 m | Valuation ($) N/A |
Financial | |||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $813.5k (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $303.3k (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit €695k (FY, 2025) | Gross profit $510.2k (FY, 2025) | Gross profit N/A |
Net income | Net income (€8.3m) (FY, 2025) | Net income ($45.3m) (FY, 2025) | Net income N/A |
For sources of this data, please see the company profile
View Company Profiles
Eyenovia
HQ
New York, US
Employees
22
Eyenovia is a late-stage biopharmaceutical company with three lead programs in glaucoma, mydriasis and dry eye with a transformative ophthalmic delivery platform.
View companyCellFE
HQ
Alameda, US
Employees
28↓ 7% decrease
CellFE is a company that develops a microfluidic device designed to deliver gene-editing molecules into the human cells.
View company